Cargando…

Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene

BACKGROUND: In clinical practice, patients with postmenopausal osteoporosis have often shown a poor response to treatment with an antiresorptive agent for several years. The purpose of this study was to investigate the efficacy of switching raloxifene with minodronate in patients who responded poorl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toda, Aska, Sawada, Kenjiro, Yoshimura, Akihiko, Nakatsuka, Erika, Kuroda, Hiromasa, Kozasa, Katsumi, Miyamoto, Mayuko, Hashimoto, Kae, Mabuchi, Seiji, Kimura, Tadashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691903/ https://www.ncbi.nlm.nih.gov/pubmed/29180905 http://dx.doi.org/10.2147/IJWH.S145805

Ejemplares similares

Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
por: Kobayashi, Masaki, et al.
Publicado: (2020)

Effect of Japanese Kampo Medicine Therapy for Menopausal Symptoms after Treatment of Gynecological Malignancy
por: Yoshimura, Akihiko, et al.
Publicado: (2018)

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary
por: Takahashi, Ryoko, et al.
Publicado: (2016)

Three years of treatment with minodronate in patients with postmenopausal osteoporosis
por: Hagino, Hiroshi, et al.
Publicado: (2011)

Minodronate for the treatment of osteoporosis
por: Ohishi, Tsuyoshi, et al.
Publicado: (2018)

Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression
por: Nakamura, Koji, et al.
Publicado: (2019)

Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types
por: Kobayashi, Masaki, et al.
Publicado: (2018)

The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma
por: Kinose, Yasuto, et al.
Publicado: (2015)

Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells
por: Yoshimura, Akihiko, et al.
Publicado: (2018)

The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer
por: Kawano, Mahiru, et al.
Publicado: (2015)

Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis
por: Lu, Hsing-Fang, et al.
Publicado: (2020)

Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene
por: Ohta, Hiroaki, et al.
Publicado: (2023)

The effects of minodronate and activated vitamin D on bone mineral density and muscle mass in postmenopausal women with osteoporosis
por: Fujimoto, Kazuki, et al.
Publicado: (2018)

Prostaglandin E2 produced by myeloid-derived suppressive cells induces cancer stem cells in uterine cervical cancer
por: Kuroda, Hiromasa, et al.
Publicado: (2018)

Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models
por: Kozasa, Katsumi, et al.
Publicado: (2019)

Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma
por: Yokoi, Eriko, et al.
Publicado: (2017)

The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis
por: Hasegawa, Eriko, et al.
Publicado: (2018)

A review of minodronic acid hydrate for the treatment of osteoporosis
por: Tanishima, Shinji, et al.
Publicado: (2013)

Utility of monthly minodronate for osteoporosis after gastrectomy: Prospective multicenter randomized controlled trials
por: Hirota, Masashi, et al.
Publicado: (2021)

Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis
por: Okazaki, R., et al.
Publicado: (2011)

Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis
por: Liu, Qingshan, et al.
Publicado: (2020)

Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update
por: Messalli, Enrico M, et al.
Publicado: (2010)

Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer
por: Shimura, Kotaro, et al.
Publicado: (2021)

Influence on the bone mineral density and bone metabolism marker after the interruption and reinitiation of monthly minodronate therapy in postmenopausal women with osteoporosis
por: Okimoto, Nobukazu, et al.
Publicado: (2018)

Comparison of clinical utilities of the platelet count and platelet-lymphocyte ratio for predicting survival in patients with cervical cancer: a single institutional study and literature review
por: Kozasa, Katsumi, et al.
Publicado: (2017)

Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)
por: Fujiwara, Saeko, et al.
Publicado: (2014)

Interleukin 6 Receptor Is an Independent Prognostic Factor and a Potential Therapeutic Target of Ovarian Cancer
por: Isobe, Aki, et al.
Publicado: (2015)

Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis
por: Islander, Ulrika, et al.
Publicado: (2011)

Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence
por: Chen, Mingsheng, et al.
Publicado: (2016)

Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study
por: Matsumoto, T., et al.
Publicado: (2008)

Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells
por: Miyamoto, Mayuko, et al.
Publicado: (2020)

Safety and efficacy of Ninjin’yoeito along with iron supplementation therapy for preoperative anemia, fatigue, and anxiety in patients with gynecological disease: an open-label, single-center, randomized phase-II trial
por: Yagi, Taro, et al.
Publicado: (2022)

Clinical relevance of circulating cell-free microRNAs in ovarian cancer
por: Nakamura, Koji, et al.
Publicado: (2016)

Effect of Raloxifene Treatment on Osteocyte Apoptosis in Postmenopausal Women
por: van Essen, Huib W., et al.
Publicado: (2007)

Pretreatment tumor-related leukocytosis misleads positron emission tomography-computed tomography during lymph node staging in gynecological malignancies
por: Mabuchi, Seiji, et al.
Publicado: (2020)

Raloxifene/Vitamin D Combination Therapy vs. Raloxifene Monotherapy on Serum 25-Hydroxy-Vitamin D Level among Postmenopausal Women with Osteoporosis or Osteopenia: A Randomized Controlled Trial
por: Lee, You-Bin, et al.
Publicado: (2022)

ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis
por: Hone, Namki, et al.
Publicado: (2022)

Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination
por: Nakatsuka, Erika, et al.
Publicado: (2017)

Effectiveness of Osteoporosis Drug in Postmenopausal Women with Spinal Compression Fracture: Combined Consecutive Therapy of Teriparatide and Raloxifene versus Bisphosphonate Single
por: Shin, Chang Jin, et al.
Publicado: (2016)

Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study
por: Suzuki, Takako, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1h6m3jbigtr2p926t45cbva9kn